{"title_page": "Camfetamine", "text_new": "{{Use dmy dates|date=January 2014}}\n{{Drugbox\n| IUPAC_name = ''N''-methyl-3-phenylbicyclo[2.2.1]heptan-2-amine\n| image = Camfetamine.svg\n| width = 160\n\n<!--Clinical data-->\n| tradename =  \n| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->\n| pregnancy_US = <!-- A / B            / C / D / X -->\n| pregnancy_category =  \n| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->\n| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->\n| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->\n| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->\n| legal_status =  \n| routes_of_administration =  \n\n<!--Pharmacokinetic data-->\n| bioavailability =  \n| protein_bound =  \n| metabolism =  \n| elimination_half-life =  \n| excretion =  \n\n<!--Identifiers-->\n| CAS_number = 92499-19-9\n| UNII_Ref = {{fdacite|correct|FDA}}\n| UNII = 3E7N2GO76U\n| ATC_prefix = none\n| ATC_suffix = \n| ATC_supplemental =  \n| PubChem = \n| ChemSpiderID = 26608747\n\n<!--Chemical data-->\n| chemical_formula =  \n| C=14 | H=19 | N=1  \n| molecular_weight = 201.307 g/mol\n| smiles = C2CC1CC2C(NC)C1c3ccccc3\n| StdInChI = 1S/C14H19N/c1-15-14-12-8-7-11(9-12)13(14)10-5-3-2-4-6-10/h2-6,11-15H,7-9H2,1H3\n| StdInChIKey = CTVMYAZECFXZLN-UHFFFAOYSA-N\n}}\n\n'''Camfetamine''' ('''N-methyl-3-phenyl-norbornan-2-amine''') is a [[stimulant]] drug closely related to the [[appetite suppressant]] [[fencamfamine]], being its N-methyl [[Homolog (chemistry)|homologue]].<ref>{{ cite patent | country = DE | status = patent | inventor = Thesing J, Seitz G, Hotovy R, Sommer S | title = Verfahren zur Herstellung analeptisch wirksamer N-substituierter Aminonorcamphanderivate bzw. von deren S\u00e4ureadditionssalzen und quatern\u00e4ren Ammoniumverbindungen | number = 1110159 | gdate = 1961-07-06 | assign1 = E. Merck AG }}</ref> It has been sold as a [[designer drug]] following the banning of [[mephedrone]] and related [[substituted cathinone]] derivatives in many countries,<ref>{{cite journal | vauthors = Kavanagh P, Angelov D, O'Brien J, Power JD, McDermott SD, Talbot B, Fox J, O'Donnell C, Christie R | display-authors = 6 | title = The synthesis and characterization N-methyl-3-phenyl-norbornan-2-amine (Camfetamine\u2122) | journal = Drug Testing and Analysis | volume = 5 | issue = 4 | pages = 247\u201353 | date = April 2013 | pmid = 22374810 | pmc =  | doi = 10.1002/dta.411 }}</ref> and reportedly has slightly stronger stimulant effects than fencamfamine, but with correspondingly more severe side effects. \n\n== See also ==\n* [[Dimethocaine]]\n* [[Ethylphenidate]]\n* [[Methiopropamine]]\n\n== References ==\n{{Reflist|2}}\n\n{{Stimulants}}\n{{Adrenergics}}\n{{Dopaminergics}}\n\n[[Category:Designer drugs]]\n[[Category:Norepinephrine-dopamine releasing agents]]\n[[Category:Stimulants]]\n\n{{nervous-system-drug-stub}}\n", "text_old": "{{Use dmy dates|date=January 2014}}\n{{Drugbox\n| IUPAC_name = ''N''-methyl-3-phenylbicyclo[2.2.1]heptan-2-amine\n| image = Camfetamine.svg\n| width = 160\n\n<!--Clinical data-->\n| tradename =  \n| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->\n| pregnancy_US = <!-- A / B            / C / D / X -->\n| pregnancy_category =  \n| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->\n| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->\n| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->\n| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->\n| legal_status =  \n| routes_of_administration =  \n\n<!--Pharmacokinetic data-->\n| bioavailability =  \n| protein_bound =  \n| metabolism =  \n| elimination_half-life =  \n| excretion =  \n\n<!--Identifiers-->\n| CAS_number = 92499-19-9\n| ATC_prefix = none\n| ATC_suffix = \n| ATC_supplemental =  \n| PubChem = \n| ChemSpiderID = 26608747\n\n<!--Chemical data-->\n| chemical_formula =  \n| C=14 | H=19 | N=1  \n| molecular_weight = 201.307 g/mol\n| smiles = C2CC1CC2C(NC)C1c3ccccc3\n| StdInChI = 1S/C14H19N/c1-15-14-12-8-7-11(9-12)13(14)10-5-3-2-4-6-10/h2-6,11-15H,7-9H2,1H3\n| StdInChIKey = CTVMYAZECFXZLN-UHFFFAOYSA-N\n}}\n\n'''Camfetamine''' ('''N-methyl-3-phenyl-norbornan-2-amine''') is a [[stimulant]] drug closely related to the [[appetite suppressant]] [[fencamfamine]], being its N-methyl [[Homolog (chemistry)|homologue]].<ref>{{ cite patent | country = DE | status = patent | inventor = Thesing J, Seitz G, Hotovy R, Sommer S | title = Verfahren zur Herstellung analeptisch wirksamer N-substituierter Aminonorcamphanderivate bzw. von deren S\u00e4ureadditionssalzen und quatern\u00e4ren Ammoniumverbindungen | number = 1110159 | gdate = 1961-07-06 | assign1 = E. Merck AG }}</ref> It has been sold as a [[designer drug]] following the banning of [[mephedrone]] and related [[substituted cathinone]] derivatives in many countries,<ref>{{cite journal | vauthors = Kavanagh P, Angelov D, O'Brien J, Power JD, McDermott SD, Talbot B, Fox J, O'Donnell C, Christie R | display-authors = 6 | title = The synthesis and characterization N-methyl-3-phenyl-norbornan-2-amine (Camfetamine\u2122) | journal = Drug Testing and Analysis | volume = 5 | issue = 4 | pages = 247\u201353 | date = April 2013 | pmid = 22374810 | pmc =  | doi = 10.1002/dta.411 }}</ref> and reportedly has slightly stronger stimulant effects than fencamfamine, but with correspondingly more severe side effects. \n\n== See also ==\n* [[Dimethocaine]]\n* [[Ethylphenidate]]\n* [[Methiopropamine]]\n\n== References ==\n{{Reflist|2}}\n\n{{Stimulants}}\n{{Adrenergics}}\n{{Dopaminergics}}\n\n[[Category:Designer drugs]]\n[[Category:Norepinephrine-dopamine releasing agents]]\n[[Category:Stimulants]]\n\n{{nervous-system-drug-stub}}\n", "name_user": "Fswitzer4", "label": "safe", "comment": "added FDA UNII to drug box", "url_page": "//en.wikipedia.org/wiki/Camfetamine"}
